Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric treatment of acute <font color="red">invasive_1</font> <font color="red">diarrhea_1</font> in children . 
<br>
<br> BACKGROUND Acute invasive diarrhea is a potentially serious condition in children . Because of the increasing resistance of enteric pathogens to commonly used oral antibiotics , intramuscular ceftriaxone has become the routine drug in the treatment of acute invasive diarrhea requiring an emergency visit in southern Israel . The inconvenience of this parenteral regimen created an increased <font color="red">need_1</font> <font color="red">for_1</font> <font color="red">oral_1</font> <font color="red">pediatric_1</font> <font color="red">formulations_1</font> for the treatment of invasive diarrhea . 
<br> OBJECTIVES To evaluate the <font color="red">efficacy_4</font> <font color="red">and_4</font> <font color="red">safety_4</font> of a suspension formulation of ciprofloxacin in the treatment of acute <font color="red">invasive_1</font> <font color="red">diarrhea_1</font> in infants and children . 
<br> PATIENTS AND METHODS From July 1996 through December 1997 , 201 evaluable children ages 6 months to 10 years ( 35% < 1 year ; 70% <3 years ) presenting with acute invasive diarrhea at the Pediatric Emergency Room were randomized to receive either ciprofloxacin suspension ( 10 mg / kg twice a day + i m placebo ; n = 95 ) or i m ceftriaxone ( 50 mg / kg / day + placebo suspension ; n = 106 ) for 3 days in a double blind manner . <font color="red">Stool_3</font> <font color="red">cultures_3</font> <font color="red">for_2</font> <font color="red">Shigella_3</font> <font color="red">,_3</font> <font color="red">Salmonella_3</font> <font color="red">,_3</font> <font color="red">Campylobacter_3</font> <font color="red">spp_3</font> <font color="red">._3</font> <font color="red">and_3</font> <font color="red">diarrheagenic_3</font> <font color="red">Escherichia_3</font> <font color="red">coli_3</font> were obtained on Days 1 , 3 , 4 to 5 and 21 + /- 5 . <font color="red">Clinical_3</font> <font color="red">response_3</font> <font color="red">and_3</font> <font color="red">safety_3</font> were assessed on Days 1 , 2 , 3 , 4 to 5 and 21 + /- 5 . 
<br> RESULTS We isolated 127 <font color="red">pathogens_2</font> from 121 ( 60% ) patients : 73 ( 57% ) <font color="red">Shigella_3</font> <font color="red">;_3</font> <font color="red">23_1</font> <font color="red">(_1</font> <font color="red">18%_1</font> <font color="red">)_1</font> <font color="red">Salmonella_3</font> <font color="red">;_3</font> <font color="red">18_1</font> <font color="red">(_1</font> <font color="red">14%_1</font> <font color="red">)_1</font> <font color="red">E._3</font> <font color="red">coli_3</font> <font color="red">;_3</font> <font color="red">and_1</font> <font color="red">13_1</font> <font color="red">(_1</font> <font color="red">10%_1</font> <font color="red">)_1</font> <font color="red">Campylobacter_3</font> <font color="red">._2</font> <font color="red">Overall_3</font> <font color="red">bacteriologic_5</font> <font color="red">eradication_5</font> <font color="red">on_1</font> <font color="red">Day_1</font> <font color="red">4_1</font> <font color="red">to_1</font> <font color="red">5_1</font> was 99% for <font color="red">Shigella_2</font> <font color="red">,_2</font> <font color="red">77%_1</font> <font color="red">for_1</font> <font color="red">Salmonella_2</font> <font color="red">and_1</font> <font color="red">77%_1</font> <font color="red">for_1</font> <font color="red">Campylobacter_2</font> <font color="red">,_2</font> with no difference between the 2 groups . <font color="red">Clinical_5</font> <font color="red">cure_5</font> <font color="red">or_5</font> <font color="red">improvement_5</font> was observed in 100 and 99% of the ciprofloxacin and ceftriaxone groups , respectively . <font color="red">Serum_5</font> <font color="red">ciprofloxacin_5</font> <font color="red">values_4</font> <font color="red">determined_1</font> <font color="red">on_1</font> <font color="red">Day_1</font> <font color="red">3_1</font> of the treatment were higher in the majority of patients than were the <font color="red">MIC50_2</font> <font color="red">and_2</font> <font color="red">MIC90_2</font> <font color="red">values_2</font> <font color="red">for_2</font> <font color="red">the_2</font> <font color="red">Shigella_2</font> <font color="red">and_2</font> <font color="red">Salmonella_2</font> <font color="red">spp_2</font> <font color="red">._2</font> <font color="red">isolated_2</font> <font color="red">._2</font> <font color="red">Possible_3</font> <font color="red">drug_5</font> <font color="red">-_5</font> <font color="red">related_5</font> <font color="red">adverse_5</font> <font color="red">events_5</font> occurred in 13 patients [ ciprofloxacin , 8 ( 8% ) ; ceftriaxone , 5 ( 4.7% ) ] and were mild and transient . <font color="red">Joint_2</font> <font color="red">examination_2</font> was normal during and after completion of therapy in all patients . 
<br> CONCLUSION Oral ciprofloxacin was as <font color="red">safe_2</font> <font color="red">and_1</font> <font color="red">effective_2</font> as intramuscular ceftriaxone for the empiric treatment of acute <font color="red">invasive_1</font> <font color="red">diarrhea_1</font> in ambulatory pediatric patients requiring an emergency room visit .